中危骨髓增生异常综合征预后的优化及阿扎胞苷的疗效 - Suppr

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes.

作者信息

Liapis Konstantinos, Papadopoulos Vasileios, Vrachiolias George, Galanopoulos Athanasios G, Papoutselis Menelaos, Papageorgiou Sotirios G, Diamantopoulos Panagiotis T, Pappa Vassiliki, Viniou Nora-Athina, Kourakli Alexandra, Τsokanas Dimitris, Vassilakopoulos Theodoros P, Hatzimichael Eleftheria, Bouronikou Eleni, Ximeri Maria, Pontikoglou Charalambos, Megalakaki Aekaterini, Zikos Panagiotis, Panayiotidis Panayiotis, Dimou Maria, Karakatsanis Stamatis, Papaioannou Maria, Vardi Anna, Kontopidou Flora, Harchalakis Nikolaos, Adamopoulos Ioannis, Symeonidis Argiris, Kotsianidis Ioannis

机构信息

Department of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece.

Department of Clinical Hematology, Georgios Gennimatas Hospital, Athens, Greece.

出版信息

Blood Cancer J. 2021 Feb 11;11(2):30. doi: 10.1038/s41408-021-00424-4.

DOI:10.1038/s41408-021-00424-4

PMID:33574231

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7878783/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91a/7878783/188c237bfde5/41408_2021_424_Fig1_HTML.jpg

相似文献

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes.中危骨髓增生异常综合征预后的优化及阿扎胞苷的疗效

Blood Cancer J. 2021 Feb 11;11(2):30. doi: 10.1038/s41408-021-00424-4.

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort.接受阿扎胞苷治疗的高危骨髓增生异常综合征患者的长期结局：GFM 同情用药项目队列的更新

Blood. 2012 Jun 21;119(25):6172-3. doi: 10.1182/blood-2012-04-422204.

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience.修订后的国际预后评分系统（IPSS）是评估接受阿扎胞苷治疗的骨髓增生异常综合征（MDS）患者预后的有力工具：法国骨髓增生异常综合征研究组（GFM）的经验。

Blood. 2012 Dec 13;120(25):5084-5. doi: 10.1182/blood-2012-09-453555.

Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system.阿扎胞苷治疗失败后骨髓增生异常综合征患者的预后预测：北美骨髓增生异常综合征联盟评分系统的验证

Haematologica. 2016 Oct;101(10):e427-e428. doi: 10.3324/haematol.2016.150714.

The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes treated with azacitidine.阿扎胞苷治疗的骨髓增生异常综合征患者循环原始粒细胞的预后价值

Med Oncol. 2019 Jan 31;36(3):25. doi: 10.1007/s12032-019-1247-3.

Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.高危骨髓增生异常综合征和急性髓系白血病患者序贯使用阿扎胞苷和来那度胺：一项单臂1/2期研究。

Lancet Haematol. 2015 Jan;2(1):e12-20. doi: 10.1016/S2352-3026(14)00026-X. Epub 2014 Dec 22.

Successful treatment of donor cell derived myelodysplastic syndrome with 5-azacytidine.5-氮杂胞苷成功治疗供体细胞衍生的骨髓增生异常综合征

Ann Biol Clin (Paris). 2017 Dec 1;75(6):713-714. doi: 10.1684/abc.2017.1293.

Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disorders.门诊骨髓增生异常综合征及相关疾病患者在阿扎胞苷给药方案依从性方面的障碍。

Support Care Cancer. 2015 Feb;23(2):303-5. doi: 10.1007/s00520-014-2502-y. Epub 2014 Nov 5.

Hematology: Azacitidine improves survival in myelodysplastic syndromes.血液学：阿扎胞苷可提高骨髓增生异常综合征患者的生存率。

Nat Rev Clin Oncol. 2009 Sep;6(9):502-3. doi: 10.1038/nrclinonc.2009.125.

Myelodysplastic syndromes (MDS).骨髓增生异常综合征（MDS）

Best Pract Res Clin Haematol. 2015 Mar;28(1):1-2. doi: 10.1016/j.beha.2014.11.007. Epub 2014 Nov 29.

本文引用的文献

Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry-based cohort study.骨髓增生异常综合征患者心血管疾病死亡的危险因素：一项基于全国登记处的队列研究。

EJHaem. 2020 Jul 1;1(1):255-261. doi: 10.1002/jha2.30. eCollection 2020 Jul.

EASIX for prediction of survival in lower-risk myelodysplastic syndromes.EASIX 预测低危骨髓增生异常综合征患者的生存情况。

Blood Cancer J. 2019 Nov 11;9(11):85. doi: 10.1038/s41408-019-0247-z.

Treatment of MDS.骨髓增生异常综合征的治疗。

Blood. 2019 Mar 7;133(10):1096-1107. doi: 10.1182/blood-2018-10-844696. Epub 2019 Jan 22.

Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R.中危 IPSS-R 骨髓增生异常综合征患者的预后表明存在不同的结果，需要超越 IPSS-R 的模型。

Am J Hematol. 2018 Oct;93(10):1245-1253. doi: 10.1002/ajh.25234. Epub 2018 Sep 26.

EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis.急性移植物抗宿主病患者的EASIX：一项回顾性队列分析。

Lancet Haematol. 2017 Sep;4(9):e414-e423. doi: 10.1016/S2352-3026(17)30108-4. Epub 2017 Jul 18.

Modeling time-to-event (survival) data using classification tree analysis.使用分类树分析对事件发生时间（生存）数据进行建模。

J Eval Clin Pract. 2017 Dec;23(6):1299-1308. doi: 10.1111/jep.12779. Epub 2017 Jul 3.

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.低危骨髓增生异常综合征患者在促红细胞生成素治疗失败后无 5q 缺失的结局。

J Clin Oncol. 2017 May 10;35(14):1591-1597. doi: 10.1200/JCO.2016.71.3271. Epub 2017 Mar 28.

Time-dependent changes in mortality and transformation risk in MDS.骨髓增生异常综合征中死亡率和转化风险的时间依赖性变化。

Blood. 2016 Aug 18;128(7):902-10. doi: 10.1182/blood-2016-02-700054. Epub 2016 Jun 22.

Decision tree methods: applications for classification and prediction.决策树方法：分类与预测应用

Shanghai Arch Psychiatry. 2015 Apr 25;27(2):130-5. doi: 10.11919/j.issn.1002-0829.215044.

Use of CHAID decision trees to formulate pathways for the early detection of metabolic syndrome in young adults.使用 CHAID 决策树制定年轻人代谢综合征早期检测的途径。

Comput Math Methods Med. 2014;2014:242717. doi: 10.1155/2014/242717. Epub 2014 Apr 10.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

本文引用的文献